Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
HomeAll NewsMost read newsBusiness Leaders Biography
Portrait de James Sapirstein
Age : 58
Public asset : 164,035 USD
Country of residence : Unknown
Linked companies : Enochian Biosciences, Inc. - AzurRx BioPharma, Inc.

Biography of James Sapirstein 
Mr. James E. Sapirstein is a Chairman & Chief Executive Officer at AzurRx BioPharma, Inc., a Chairman & Chief Executive Officer at Marizyme, Inc., an Independent Director at Enochian Biosciences, Inc., a Director & Member-Emerging Companies at Biotechnology Innovation Organization and an Independent Director at Blue Water Acquisition Corp. He is on the Board of Directors at Enochian Biosciences, Inc., Leading Biosciences, Inc., Biotechnology Innovation Organization, BioNJ, Inc., Clinical Supplies Management, Inc. and Blue Water Acquisition Corp. Mr. Sapirstein was previously employed as an Independent Director by NanoViricides, Inc., an Independent Director by Panther Biotechnology, Inc., an Independent Director by RespireRx Pharmaceuticals, Inc., a Chief Executive Officer & Director by ContraVir Pharmaceuticals, Inc., a Chief Executive Officer & Director by Alliqua, Inc., a President, Chief Executive Officer & Director by Tobira Therapeutics, Inc. /Old/, an Executive Vice President-Metabolic & Endocrinology by Serono, Inc., a Global Marketing Lead by Gilead Sciences, Inc., a Director-International Marketing by Bristol Myers Squibb Co., a Principal by Eli Lilly & Co., and a Product Director by Hoffmann-La Roche, Inc. He received his undergraduate degree from Rutgers State University of New Jersey and an MBA from Fairleigh Dickinson University.


Current positions of James Sapirstein 
Holdings of James Sapirstein 
James Sapirstein : Personal Network 
Most Read News 
09/04BERNARD ARNAULT : There is no conflict with Arnault
RE
09/07GEORGE SOROS : Soros says BlackRock's China investments likely to lose money - WSJ
RE
09/14BRAD SMITH : Microsoft to buy back up to $60 billion in shares; names Brad Smith vice chair
RE
09/09FRANCESCO GAETANO CALTAGIRONE : Italy's Caltagirone ups Generali stake to just over 6%
RE
09/14CATHIE WOOD : ARK Invest's Wood expects market rotation back to growth stocks
RE
09/09ELON MUSK : Tesla's Musk asks staff to 'go super hardcore' to ensure decent Q3 delivery number
RE
09/13MARTIN SORRELL : Sorrell's S4 Capital raises annual profit outlook for a third time
RE
09/08ELON MUSK : Amazon.com goes for jugular in FCC spat with SpaceX's Musk
RE
09/08BILL GATES : Bill Gates' investment firm to take control of Four Seasons in $2.21 billion deal
RE
09:11aSTELIOS HAJI-IOANNOU : EasyJet shareholder Stelios Haji-Ioannou shuns rights issue -source
RE
More news


© 2021 People and Ownership :   
James Sapirstein : Connections 


Latest news about James Sapirstein 
08/18AZURRX BIOPHARMA : Reports Positive Topline Results in Study of Potential Drug for Severe Exocrine Pancreatic Insufficiency; Shares Rise Pre-Bell
MT
07/12Marizyme Names Vithal Dhaduk as Interim Chief Executive Officer
MT
06/28Marizyme, Inc. Announces Executive Changes
CI
06/28Marizyme, Inc Provides Information to the shareholders
CI
06/28James Sapirstein Resigns as Interim Chief Executive Officer of Marizyme, Inc
CI
03/31AzurRx BioPharma Provides Key Takeaways from Phase 2b OPTION 2 Clinical Trial Topline Results Conference Call
CI
03/19Marizyme, Inc. Announces Executive Changes
CI
More news